Sionna Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Cloonan
- Full Time Employees
- 41
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 21 Hickory Drive Suite 500 Waltham MA United States of America 02451
- IPO Date
- Feb 7, 2025
- CIK
- 0002036042
- Website
- sionnatx.com
- Similar Companies
- Business
- Sionna Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for diseases caused by dysregulation of RNA. The company’s core products and services include the discovery and development of small molecule and RNA-targeted therapeutics designed to modulate RNA splicing and improve gene expression. Sionna Therapeutics utilizes proprietary RNA-targeting platforms to create treatments for genetically defined patient populations, primarily in the areas of neurology, ophthalmology, and other rare diseases. The company operates primarily in the United States and internationally as it advances its pipeline through clinical trials. Founded in 2018, Sionna Therapeutics is headquartered in Cambridge, Massachusetts. Recent major company developments include strategic collaborations and advancements in its drug pipeline with a focus on moving lead candidates into clinical stages. Sionna has also expanded its research capabilities through partnerships and has progressed new product candidates into early clinical trials within the last one to two years. These steps emphasize Sionna’s commitment to translating its platform technology into novel therapeutic candidates addressing unmet medical needs in precision RNA medicine. The company continues to broaden its presence in biopharmaceutical innovation through strategic alliances and operational growth consistent with its mission to develop RNA-targeted therapies. Sionna Therapeutics operates within the biotechnology and pharmaceutical industry segments, targeting patients with rare and serious diseases caused by RNA splicing errors. Its customer base includes research institutions, healthcare providers, and ultimately patients requiring advanced precision medical treatments. It functions independently and may engage in collaborations with larger pharmaceutical firms to leverage its RNA-focused technologies. The company’s geographic footprint spans the US and global markets through clinical development and research partnerships.
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
First Look: eBay rebuffs GME, oil swings, CEOs to China
Sionna Therapeutics Reports First Quarter 2026 Financial Results
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $2,128,201.14 in Stock
Sionna Therapeutics (NASDAQ:SION) Director Sells $2,128,201.14 in Stock
Sionna Therapeutics (NASDAQ:SION) Director Sells $10,287,918.04 in Stock
Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $10,528,924.32 in Stock
Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $10,287,918.04 in Stock
Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $10,528,924.32 in Stock
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
Orbimed Advisors Llc Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock
Peter Thompson Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026